SMMT — Summit Therapeutics Share Price
0.000.00%
Last trade - 00:00- $18.15bn
- $17.74bn
- 36
- 20
- 97
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 46.7 | ||
| Price to Tang. Book | 46.92 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.38% | ||
| Return on Equity | -94.9% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.86 | 1.81 | 0.7 | n/a | n/a | n/a | 52.01 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Directors
- Robert Duggan CHM (77)
- Michael Donaldson CFO (44)
- Mahkam Zanganeh COO (50)
- David Powell CSO (52)
- Kenneth Clark DRC (62)
- Urte Gayko DRC (44)
- Ujwala Mahatme IND (57)
- Rainer Erdtmann NID (57)
- Manmeet Soni NID (43)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 17th, 2020
- Public Since
- October 14th, 2004
- No. of Shareholders
- 139
- No. of Employees
- 159
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 737,626,004
- Address
- 601 Brickell Key Drive, Suite 1000, MIAMI, 33131
- Web
- https://www.smmttx.com/
- Phone
- +1 3052032034
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for SMMT
Summit Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Summit Therapeutics Inc Earnings Release
Similar to SMMT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Summit Therapeutics share price?
As of Today at 23:29 UTC, shares in Summit Therapeutics are trading at $24.61. This share price information is delayed by 15 minutes.
How has the Summit Therapeutics share price performed this year?
Shares in Summit Therapeutics last closed at $24.61 and the price had moved by +589.36% over the past 365 days. In terms of relative price strength the Summit Therapeutics share price has outperformed the S&P500 Index by +548.19% over the past year.
What are the analyst and broker recommendations for Summit Therapeutics?
The overall consensus recommendation for Summit Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Summit Therapeutics dividend yield?
Summit Therapeutics does not currently pay a dividend.
Does Summit Therapeutics pay a dividend?
Summit Therapeutics does not currently pay a dividend.
When does Summit Therapeutics next pay dividends?
Summit Therapeutics does not currently pay a dividend.
How do I buy Summit Therapeutics shares?
To buy shares in Summit Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Summit Therapeutics?
As of the previous close price of $24.61, shares in Summit Therapeutics had a market capitalisation of $18.15bn.
Where are Summit Therapeutics shares listed?
Here are the trading details for Summit Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: SMMT
What kind of share is Summit Therapeutics?
Based on an overall assessment of its quality, value and momentum Summit Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Summit Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Summit Therapeutics is $31.00. That is 25.97% above the last closing price of $24.61.
Analysts covering Summit Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.42 for the next financial year.
Find out moreWhat is the trend in the Summit Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Summit Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +28.58%.
As of the last closing price of $24.61, shares in Summit Therapeutics were trading +36.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Summit Therapeutics PE Ratio?
The Summit Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Summit Therapeutics?
Summit Therapeutics' management team is headed by:
- Robert Duggan - CHM
- Michael Donaldson - CFO
- Mahkam Zanganeh - COO
- David Powell - CSO
- Kenneth Clark - DRC
- Urte Gayko - DRC
- Ujwala Mahatme - IND
- Rainer Erdtmann - NID
- Manmeet Soni - NID